Skip to main content
Digital Recording

Emerging Psychedelic Treatments: Opportunities and Challenges

Average Rating:
Michael Mithoefer, MD |  Rick Doblin, PhD
3 Hours 55 Minutes
Mar 12, 2022
Product Code:
Media Type:
Digital Recording
Never expires.


Media reports about psychedelics are now more likely to be about emerging therapeutic uses than about raves or drug busts. Are your clients asking you about them, are you curious about their potential to enliven psychotherapy? Clinical trials of MDMA and psilocybin as catalysts to psychotherapy are in final stages of FDA trials. Results show large treatment effects for PTSD, depression, and relationship satisfaction in couples. In this treatment model, the drugs are administered only a few times in a course of psychotherapy aimed at accessing the individual’s own healing potential. Guided in this recording by the psychiatrist at the helm of the MDMA-assisted psychotherapy trials, you’ll explore:

  • The rationale for using drugs like MDMA as catalysts for psychotherapy
  • How to understand the clinical trial results
  • The MDMA-assisted psychotherapy process, illustrated with video clips
  • The challenges of maintaining quality and equitable access as these treatments approach likely FDA approval



This online program is worth 4 hours CPD.



Michael Mithoefer, MD's Profile

Michael Mithoefer, MD Related seminars and products

Michael Mithoefer, MD, is clinical assistant professor of psychiatry at the Medical University of South Carolina. In 2009, he completed & published the first FDA approved clinical trial of MDMA assisted psychotherapy for treatment-resistant PTSD, followed by completion of a Phase II trial. He is overseeing a multisite Phase III study of MDMA-assisted psychotherapy in 13 sites around the US (including the Trauma Research Foundation), and another MDMA-assisted psychotherapy multisite study in Europe and Israel.


Speaker Disclosures:
Financial: Dr. Michael Mithoefer has employment relationships with Bassett Healthcare Network, Medical University of South Carolina, and MAPS Public Benefit Corporation. He has an ownership interest in Awakn Life Sciences and serves on the scientific advisory board. Dr. Mithoefer receives a speaking honorarium and recording royalties from PESI, Inc.
Non-financial: Dr. Michael Mithoefer is a fellow of the American Psychiatric Association.

Rick Doblin, PhD's Profile

Rick Doblin, PhD Related seminars and products

Rick Doblin, Ph.D., Executive Director, Multidisciplinary Association for Psychedelic Studies (MAPS); chair of the board of directors MAPS Public Benefit Corporation.


Speaker Disclosures:
Financial: Richard Doblin has an employment relationship with Multidisciplinary Association for Psychedelic Studies, Inc. He receives a speaking honorarium and recording royalties from PESI, Inc. He has no relevant financial relationships with ineligible organizations.
Non-financial: Richard Doblin has no relevant non-financial relationships.


  1. Appraise the rationale for researching MDMA as an adjunct to psychotherapy.
  2. Analyze the results of Phase 2 and a recent Phase 3 Clinical Trial of MDMA-assisted Psychotherapy for PTSD.
  3. Catalogue the major indications for which psilocybin has been studied.
  4. Analyze the therapeutic method used in trials of MDMA-assisted psychotherapy for PTSD.
  5. Quantify 2 physiological effects of MDMA that relate to medical contraindications.


  • Background and effects of MDMA
    • Case reports of clinical use before MDMA was placed in schedule 1
    • Neurochemistry and physiological effects
  • Results of clinical trials of MDMA-assisted psychotherapy
    • Timeline of research in past 20 years
    • Results of Phase 2 and Phase 3 clinical trials
  • Psilocybin research
    • Brief review of indications studied in psilocybin clinical trials
    • Similarities and differences between therapeutic approaches in studies of psilocybin and studies of MDMA-assisted psychotherapy.
  • The therapeutic method used in MDMA trials
    • The therapy Manual
    • Adherence criteria
    • Clinical vignettes from Clinical Trials illustrated with quotes and video clips
  • The likely future roles of psychedelics in psychiatry and psychological

Target Audience

  • Psychologists
  • Physicians
  • Addiction Counselors
  • Counselors
  • Social Workers
  • Marriage & Family Therapists
  • Art Therapists
  • Nurses
  • Other Behavioral Health Professionals



Overall:      4.9

Total Reviews: 57

Satisfaction Guarantee
Your satisfaction is our goal and our guarantee. Concerns should be addressed to or call 01235847393.

Please wait ...

Back to Top